title: Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome.
abstract: We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant was 30 (4-206) months and most subjects were with multiply relapsed/ refractory disease. The majority (64%) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P=0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19% (95% confidence interval (CI) 12-27%) and 22% (95% CI 15-31%), respectively. Risk of disease progression was 50% (95% CI 41-60%) at 1 year and 61% (95% CI 50-71%) at 5 years. PFS at 1 and 5 years was 31% (95% CI 22-40%) and 17% (95% CI 9-26%), respectively. OS at 1 and 5 years was 54% (95% CI 45-63%) and 32% (95% CI 22-44%), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.
authors: Emory University Hospital, Atlanta, GA, USA.
authors: M J
authors: MJ
authors: Lechowicz
authors: Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.
authors: H M
authors: HM
authors: Lazarus
authors: Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
authors: J
authors: J
authors: Carreras
authors: Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA, USA.
authors: G G
authors: GG
authors: Laport
authors: Dana Farber Cancer Institute, Boston, MA, USA.
authors: C S
authors: CS
authors: Cutler
authors: Our Lady of Mercy Medical Center, Bronx, NY, USA.
authors: P H
authors: PH
authors: Wiernik
authors: Pediatric Hematology/Oncology/BMT, All Children's Hospital, St. Petersburg, FL, USA.
authors: G A
authors: GA
authors: Hale
authors: South Florida Bone Marrow Stem Cell Transplant Institute, Boynton Beach, FL, USA.
authors: D
authors: D
authors: Maharaj
authors: Section of Hematology, Division of Experimental Medicine, Department of Medicine, Imperial College, London, UK.
authors: R P
authors: RP
authors: Gale
authors: Calvary Mater Newcastle, HAPS-Pathology North, University of Newcastle, New South Wales, Australia.
authors: P A
authors: PA
authors: Rowlings
authors: South Texas Veterans Health Care System and University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
authors: C O
authors: CO
authors: Freytes
authors: Baylor University Medical Center, Dallas, TX, USA.
authors: A M
authors: AM
authors: Miller
authors: Division of Hematology/Oncology, The Nebraska Medical Center, Omaha, NE, USA.
authors: J M
authors: JM
authors: Vose
authors: Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR, USA.
authors: R T
authors: RT
authors: Maziarz
authors: Barts Cancer Institute, Queen Mary University of London, London, UK.
authors: S
authors: S
authors: Montoto
authors: Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
authors: D G
authors: DG
authors: Maloney
authors: Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
authors: P N
authors: PN
authors: Hari
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D064591:Allografts; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000401:mortality / Q000628:therapy; D012189:Retrospective Studies; D012307:Risk Factors; D012751:Sezary Syndrome / Q000401:mortality / Q000628:therapy; D015996:Survival Rate; D019172:Transplantation Conditioning